TABLE 2.
Cox regression for recurrence-free survival
| Univariate analysis | Multivariable analysis A: number of POCs | Multivariable analysis B: grade of POCs | Multivariable analysis C: infectious POCs | Multivariable analysis D: renal POCs | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age | 1.00 (0.99–1.01) | 0.95 | – | – | – | – | – | – | – | – |
| BMI | 1.03 (1.01–1.05) | 0.01 | 1.03 (1.01–1.05) | < 0.01 | 1.03 (1.01–1.05) | < 0.01 | 1.03 (1.01–1.05) | < 0.01 | 1.03 (1.01–1.05) | < 0.01 |
| NAC | 0.51 (0.35–0.77) | < 0.01 | 0.89 (0.64–1.23) | 0.46 | 0.56 (0.35–0.91) | 0.02 | 0.56 (0.35–0.91) | 0.02 | 0.56 (0.35–0.90) | 0.02 |
| Neoadjuvant CRT | 1.5 (0.99–2.21) | 0.06 | – | – | – | – | – | – | – | – |
| Adjuvant chemotherapy | 1.10 (0.78–1.54) | 0.58 | ||||||||
| Delay in adjuvant therapy | 1.28 (0.68–2.43) | 0.44 | ||||||||
| Tumor differentiation | ||||||||||
| Well | Reference | – | – | – | – | – | – | – | – | |
| Moderate | 0.67 (0.27–1.65) | 0.38 | – | – | – | – | – | – | – | – |
| Poor | 0.83 (0.29–2.37) | 0.73 | – | – | – | – | – | – | – | – |
| Undifferentiated | 1.53 (0.29–7.88) | 0.62 | – | – | – | – | – | – | – | – |
| Pathologic stage (AJCC 8th edition) | ||||||||||
| I | Reference | Reference | Reference | Reference | Reference | |||||
| II | 3.01 (1.80–5.03) | < 0.01 | 2.65 (1.69–4.14) | < 0.01 | 2.47 (1.44–4.25) | < 0.01 | 2.47 (1.44–4.25) | < 0.01 | 2.52 (1.47–4.33) | < 0.01 |
| III | 3.84 (2.41–6.14) | < 0.01 | 3.66 (2.44–5.48) | < 0.01 | 2.85 (1.75–4.66) | < 0.01 | 2.85 (1.75–4.66) | < 0.01 | 3.06 (1.87–5.00) | < 0.01 |
| Number of POCs | ||||||||||
| No POCs | Reference | Reference | ||||||||
| Single | 1.89 (1.41–2.54) | < 0.01 | 1.68 (1.17–2.42) | < 0.01 | ||||||
| Multiple | 1.80 (1.36–2.38) | < 0.01 | 1.76 (1.24–2.51) | < 0.01 | ||||||
| Grade of POCs | ||||||||||
| No POCs | Reference | – | – | Reference | – | – | – | – | ||
| Minor POCs | 1.47 (0.95–2.29) | 0.08 | – | – | 1.37 (0.84–2.24) | 0.20 | – | – | – | – |
| Major POCs | 2.75 (1.78–4.26) | < 0.01 | – | – | 2.26 (1.39–3.67) | < 0.01 | – | – | – | – |
| Type of POCs | – | – | ||||||||
| No POCs | Reference | – | – | – | – | Reference | – | – | ||
| Other POCs | 2.63 (1.62–4.27) | < 0.01 | – | – | – | – | 1.48 (0.96–2.29) | 0.08 | – | – |
| Infectious POCs | 3.66 (1.75–7.62) | < 0.01 | – | – | – | – | 2.13 (1.27–3.58) | < 0.01 | – | – |
| Type of POCs | ||||||||||
| No POCs | Reference | – | – | – | – | – | – | Reference | ||
| Other POCs | 1.88 (1.31–2.69) | < 0.01 | – | – | – | – | – | – | 1.61 (1.08–2.39) | 0.02 |
| Renal POCs | 3.65 (1.75–7.62) | < 0.01 | – | – | – | – | – | – | 3.18 (1.49–6.75) | < 0.01 |
Bold data indicates statistical significance
HR hazard ratio, CI confidence interval, NAC neoadjuvant chemotherapy, CRT chemoradiotherapy, POCs postoperative complications, BMI body mass index, AJCC American Joint Committee on Cancer Multivariable analyses were omitted from the table for cardiopulmonary, thromboembolic, and intestinal dysmotility type of POC